TYPE,NAME,NODE_ID,source_primary,source_secondary,title,source_link,source_date,pubmed_id,country_of_origin
disease,dementia/parkinsonism with non-Alzheimer amyloid plaques,n_0,,,,,,,
disease,Alzheimer disease,n_4,,,,,,,
disease,"Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology",n_39,,,,,,,
disease,familial Alzheimer disease,n_44,,,,,,,
disease,Alzheimer disease without neurofibrillary tangles,n_133,,,,,,,
disease,"Alzheimer disease, susceptibility to, mitochondrial",n_351,,,,,,,
pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,n_373,,,,,,,
Stage,Mild (MMSE 21-26),n_399,,,,,,,
Stage,Moderate (MMSE 10-20),n_402,,,,,,,
Stage,Severe (MMSE <10),n_405,,,,,,,
Treatment,Donepezil Treatment (NICE),n_417,,,,,,,
Treatment,Rivastigmine Treatment (NICE),n_418,,,,,,,
Treatment,Rivastigmine Patch Treatment (NICE),n_419,,,,,,,
Treatment,Galantamine Treatment (NICE),n_420,,,,,,,
Treatment,Galantamine Treatment moderate hepatic impairment (NICE),n_421,,,,,,,
Treatment,Memantine Treatment (NICE),n_422,,,,,,,
Treatment,Memantine Treatment renal impairment 1 (NICE),n_423,,,,,,,
Treatment,Memantine Treatment renal impairment 2 (NICE),n_424,,,,,,,
Treatment,Memantine Treatment renal impairment 3 (NICE),n_425,,,,,,,
Treatment,Haloperidol Treatment (NICE),n_426,,,,,,,
Treatment,Risperidone Treatment (NICE),n_427,,,,,,,
Step,Donepezil Treatment (NICE) (1),n_431,,,,,,,
Dosage,Donepezil 5mg/day,n_432,,,,,,,
Step,Donepezil Treatment (NICE) (2),n_434,,,,,,,
Step,Galantamine Treatment (NICE) (1),n_441,,,,,,,
Dosage,Galantamine 8mg/day,n_442,,,,,,,
Step,Galantamine Treatment (NICE) (2),n_444,,,,,,,
Dosage,Galantamine 16mg/day,n_445,,,,,,,
Step,Galantamine Treatment (NICE) (3),n_447,,,,,,,
Step,Galantamine Treatment moderate hepatic impairment (NICE) (1),n_451,,,,,,,
Step,Galantamine Treatment moderate hepatic impairment (NICE) (2),n_454,,,,,,,
Dosage,Galantamine 8-16mg/day,n_455,,,,,,,
Step,Rivastigmine Patch Treatment (NICE) (1),n_463,,,,,,,
Dosage,Rivastigmine Patch 4.6mg/day,n_464,,,,,,,
Step,Rivastigmine Patch Treatment (NICE) (2),n_466,,,,,,,
Dosage,Rivastigmine Patch 9.5mg/day,n_467,,,,,,,
Step,Rivastigmine Patch Treatment (NICE) (3),n_469,,,,,,,
Dosage,Risperidone 0.5-5 mg/day,n_493,,,,,,,
drug,Donepezil,n_494,,,,,,,
drug,Galantamine,n_516,,,,,,,
drug,Rivastigmine,n_552,,,,,,,
drug,Memantine,n_593,,,,,,,
drug,Haloperidol,n_612,,,,,,,
drug,Risperidone,n_636,,,,,,,
Therapy,Cognitive Stimulation Therapy,n_668,,,,,,,
Therapy,Reminiscence Therapy,n_669,,,,,,,
Therapy,Behavioral Management,n_670,,,,,,,
Therapy,Music Therapy,n_671,,,,,,,
Treatment,Donepezil Treatment (之),n_769,,,,,,,
Step,Donepezil Treatment (之) (1),n_771,,,,,,,
Step,Donepezil Treatment (之) (2),n_774,,,,,,,
Treatment,Rivastigmine Treatment (之),n_776,,,,,,,
Treatment,Galantamine Treatment (之),n_779,,,,,,,
Step,Galantamine Treatment (之) (1),n_781,,,,,,,
Step,Galantamine Treatment (之) (2),n_783,,,,,,,
Treatment,Memantine Treatment (之),n_785,,,,,,,
drug,Rivastigmine patch,n_794,,,,,,,
Stage,Mild  (ADAS-Cog),n_830,,,,,,,
Stage,Moderate (ADAS-Cog),n_832,,,,,,,
Stage,Severe (ADAS-Cog),n_834,,,,,,,
Treatment,Donepezil Treatment  (MaHTAS),n_855,,,,,,,
Treatment,Rivastigmine Patch Treatment (MaHTAS),n_856,,,,,,,
Treatment,Rivastigmine Treatment (MaHTAS),n_857,,,,,,,
Treatment,Galantamine Treatment (MaHTAS),n_858,,,,,,,
Treatment,Memantine Treatment (MaHTAS),n_859,,,,,,,
Treatment,Donepezil Treatment (MaHTAS),n_861,,,,,,,
Dosage,Donepezil 10 mg/day,n_863,,,,,,,
Dosage,Rivastigmine 6 - 12 mg/day*2,n_868,,,,,,,
Dosage,Rivastigmine Patch 9.5 mg/day,n_873,,,,,,,
drug,Rivastigmine Patch,n_889,,,,,,,
Therapy,Exercise,n_900,,,,,,,
Therapy,Diet and supplement,n_901,,,,,,,
Treatment,Donepezil Treatment (AmericanAcademy of Family Physicians),n_918,,,,,,,
Treatment,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),n_919,,,,,,,
Treatment,Rivastigmine Treatment (AmericanAcademy of Family Physicians),n_920,,,,,,,
Treatment,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),n_921,,,,,,,
Treatment,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),n_922,,,,,,,
Treatment,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),n_923,,,,,,,
Treatment,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),n_924,,,,,,,
Treatment,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),n_925,,,,,,,
Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (1),n_929,,,,,,,
Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (2),n_932,,,,,,,
Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (3),n_935,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (1),n_941,,,,,,,
Dosage,Rivastigmine 1.5 mg/day*2,n_942,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (2),n_944,,,,,,,
Dosage,Rivastigmine 3 mg/day*2,n_945,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),n_947,,,,,,,
Dosage,Rivastigmine 4.5 mg/day*2,n_948,,,,,,,
Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),n_956,,,,,,,
Dosage,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),n_957,,,,,,,
Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),n_959,,,,,,,
Dosage,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),n_960,,,,,,,
Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (3),n_962,,,,,,,
Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),n_968,,,,,,,
Dosage,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),n_969,,,,,,,
Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),n_971,,,,,,,
Dosage,Galantamine 8 mg/day*2,n_972,,,,,,,
Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),n_974,,,,,,,
Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),n_980,,,,,,,
Dosage,Galantamine 8 mg/day,n_981,,,,,,,
Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),n_983,,,,,,,
Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),n_986,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),n_992,,,,,,,
Dosage,Memantine 5mg/day,n_993,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),n_995,,,,,,,
Dosage,Memantine 5mg/day*2,n_996,,,,,,,
Dosage,Memantine 10mg/day,n_1000,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),n_1002,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (4),n_1003,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),n_1010,,,,,,,
Dosage,Memantine 7 mg/day,n_1011,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),n_1013,,,,,,,
Dosage,Memantine 14 mg/day,n_1014,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),n_1016,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (4),n_1019,,,,,,,
Dosage,Memantine 21 mg/day,n_1020,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (5),n_1022,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),n_1030,,,,,,,
Dosage,Donepezil 10mg/day,n_1034,,,,,,,
Dosage,"Vitamin E 1,000IU/day*2",n_1035,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),n_1037,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),n_1044,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),n_1051,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (5),n_1058,,,,,,,
drug,Vitamin E,n_1097,,,,,,,
Therapy,Enjoyable leisure activities,n_1114,,,,,,,
Therapy,Mental stimulation programs,n_1115,,,,,,,
Therapy,Occupational therapy training in coping strategies and cognitive aides,n_1116,,,,,,,
Therapy,Structured physical exercise programs,n_1117,,,,,,,
Stage,拇,n_1132,,,,,,,
Stage,銝剜,n_1137,,,,,,,
Stage,,n_1142,,,,,,,
Treatment,Donepezil Treatment (箔葉璁桃蜇),n_1148,,,,,,,
Step,Donepezil Treatment (箔葉璁桃蜇) (1),n_1150,,,,,,,
Dosage,Donepezil 5 mg/day,n_1151,,,,,,,
Step,Donepezil Treatment (箔葉璁桃蜇) (2),n_1153,,,,,,,
Treatment,Rivastigmine Treatment (箔葉璁桃蜇),n_1157,,,,,,,
Step,Rivastigmine Treatment (箔葉璁桃蜇) (1),n_1159,,,,,,,
Dosage,Rivastigmine 1.5 mg/day,n_1160,,,,,,,
Step,Rivastigmine Treatment (箔葉璁桃蜇) (2),n_1162,,,,,,,
Step,Rivastigmine Treatment (箔葉璁桃蜇) (3),n_1165,,,,,,,
Treatment,Rivastigmine Patch Treatment (箔葉璁桃蜇),n_1168,,,,,,,
Step,Rivastigmine Patch Treatment (箔葉璁桃蜇) (1),n_1170,,,,,,,
Dosage,Rivastigmine Patch 4.6 mg/day,n_1171,,,,,,,
Step,Rivastigmine Patch Treatment (箔葉璁桃蜇) (2),n_1173,,,,,,,
Treatment,Galantamine Treatment (箔葉璁桃蜇),n_1176,,,,,,,
Step,Galantamine Treatment (箔葉璁桃蜇) (1),n_1178,,,,,,,
Step,Galantamine Treatment (箔葉璁桃蜇) (2),n_1181,,,,,,,
Treatment,Memantine Treatment (箔葉璁桃蜇),n_1184,,,,,,,
Step,Memantine Treatment (箔葉璁桃蜇) (1),n_1186,,,,,,,
Step,Memantine Treatment (箔葉璁桃蜇) (2),n_1189,,,,,,,
Treatment,Memantine Treatment 賭雿唾 (箔葉璁桃蜇),n_1193,,,,,,,
Step,Memantine Treatment 賭雿唾 (箔葉璁桃蜇),n_1194,,,,,,,
Therapy,Cognitive Activities,n_1256,,,,,,,
Therapy,Music Therapy Groups,n_1257,,,,,,,
Therapy,Art Creation,n_1258,,,,,,,
Therapy,Exercise Groups,n_1259,,,,,,,
Therapy,Reality Orientation Therapy,n_1260,,,,,,,
Therapy,Dance Therapy,n_1261,,,,,,,
Therapy,Horticulture Therapy,n_1262,,,,,,,
Therapy,Aromatherapy,n_1263,,,,,,,
Therapy,Pet Therapy,n_1264,,,,,,,
Therapy,Doll Therapy,n_1265,,,,,,,
Therapy,Sensory Stimulation,n_1266,,,,,,,
Stage,Early stage(GDS 2-5),n_1296,,,,,,,
Stage,Middle stage (GDS 4-6),n_1299,,,,,,,
Stage,Late stage (GDS 7),n_1303,,,,,,,
Treatment,Combined Donepezil and Memantine Treatment (Japanese Society of Neurology),n_1350,,,,,,,
Treatment,Donepezil Treatment (Japanese Society of Neurology),n_1353,,,,,,,
Treatment,Galantamine Treatment (Japanese Society of Neurology),n_1357,,,,,,,
Treatment,Rivastigmine Treatment (Japanese Society of Neurology),n_1361,,,,,,,
Treatment,Rivastigmine Patch Treatment (Japanese Society of Neurology),n_1365,,,,,,,
Treatment,Memantine Treatment (Japanese Society of Neurology),n_1369,,,,,,,
Treatment,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),n_1373,,,,,,,
Therapy,Exercise therapy,n_1379,,,,,,,
Therapy,Music therapy,n_1380,,,,,,,
Stage,(MCI) due to Alzheimer's disease,n_1383,,,,,,,
Stage,Early stage(mild),n_1385,,,,,,,
Stage,Middle stage (moderate),n_1391,,,,,,,
Stage,Late stage (severe),n_1397,,,,,,,
Stage,MCI due to Alzheimer's disease,n_1400,,,,,,,
Treatment,Donanemab Treatment (Alzheimer's Association),n_1423,,,,,,,
Treatment,Lecanemab (Alzheimer's Association),n_1426,,,,,,,
Treatment,Donepezil Treatment (Alzheimer's Association),n_1429,,,,,,,
Treatment,Rivastigmine Treatment (Alzheimer's Association),n_1432,,,,,,,
Treatment,Galantamine Treatment (Alzheimer's Association),n_1435,,,,,,,
Treatment,Memantine Treatment (Alzheimer's Association),n_1438,,,,,,,
Treatment,Memantine + Donepezil (Alzheimer's Association),n_1441,,,,,,,
Treatment,Brexpiprazole Treatment (Alzheimer's Association),n_1445,,,,,,,
Treatment,Suvorexant Treatment (Alzheimer's Association),n_1448,,,,,,,
drug,Donanemab,n_1451,,,,,,,
drug,Lecanemab,n_1453,,,,,,,
drug,Brexpiprazole,n_1473,,,,,,,
drug,Suvorexant,n_1478,,,,,,,
Treatment,Donepezil Treatment (Demenzen),n_1513,,,,,,,
Treatment,Rivastigmine Treatment (Demenzen),n_1514,,,,,,,
Treatment,Galantamine Treatment (Demenzen),n_1515,,,,,,,
Treatment,Memantine Treatment (Demenzen),n_1516,,,,,,,
Dosage,Rivastigmine 3mg/day,n_1538,,,,,,,
Treatment,Donepezil Treatment (CDPC),n_1581,,,,,,,
Treatment,Rivastigmine Treatment (CDPC),n_1582,,,,,,,
Treatment,Galantamine Treatment (CDPC),n_1583,,,,,,,
Treatment,Memantine Treatment (CDPC),n_1584,,,,,,,
Dosage,Galantamine 5mg/day,n_1594,,,,,,,
Dosage,Rivastigmine 5mg/day,n_1606,,,,,,,
drug,Souvenaid,n_1629,,,,,,,
drug,Ovid,n_1634,,,,,,,
drug,Methylphenidate,n_1639,,,,,,,
drug,State,n_1645,,,,,,,
drug,April,n_1650,,,,,,,
drug,Latrepirdine,n_1663,,,,,,,
drug,Tacrine,n_1666,,,,,,,
drug,Medicine,n_1678,,,,,,,
drug,Symbol,n_1696,,,,,,,
drug,Clarivate,n_1699,,,,,,,
drug,Relevant,n_1703,,,,,,,
drug,Bristol,n_1730,,,,,,,
drug,Baseline,n_1740,,,,,,,
drug,Brazil,n_1753,,,,,,,
drug,Dopamine,n_1759,,,,,,,
drug,Control,n_1768,,,,,,,
drug,Trail,n_1771,,,,,,,
drug,School,n_1779,,,,,,,
drug,Moderate,n_1787,,,,,,,
drug,Acetylcholine,n_1808,,,,,,,
drug,Significant,n_1809,,,,,,,
drug,Aberrant,n_1811,,,,,,,
drug,Dexmedetomidine,n_1813,,,,,,,
effect/phenotype,Parkinsonism,n_1825,,,,,,,
effect/phenotype,Dementia,n_1826,,,,,,,
effect/phenotype,Substantia nigra gliosis,n_1827,,,,,,,
effect/phenotype,Autosomal dominant inheritance,n_1828,,,,,,,
effect/phenotype,Dysphagia,n_1829,,,,,,,
effect/phenotype,Optic ataxia,n_1830,,,,,,,
effect/phenotype,Gait disturbance,n_1831,,,,,,,
effect/phenotype,Memory impairment,n_1832,,,,,,,
effect/phenotype,Babinski sign,n_1833,,,,,,,
effect/phenotype,Seizure,n_1834,,,,,,,
effect/phenotype,Cerebral cortical atrophy,n_1835,,,,,,,
effect/phenotype,Apraxia,n_1836,,,,,,,
effect/phenotype,Lower limb hyperreflexia,n_1837,,,,,,,
effect/phenotype,Dysarthria,n_1838,,,,,,,
effect/phenotype,Spastic tetraparesis,n_1839,,,,,,,
effect/phenotype,Adult onset,n_1840,,,,,,,
effect/phenotype,Neurofibrillary tangles,n_1841,,,,,,,
effect/phenotype,Abnormality of extrapyramidal motor function,n_1842,,,,,,,
effect/phenotype,Agnosia,n_1843,,,,,,,
effect/phenotype,Personality changes,n_1845,,,,,,,
effect/phenotype,Myoclonus,n_1847,,,,,,,
effect/phenotype,Rapidly progressive,n_1848,,,,,,,
effect/phenotype,Decreased level of GABA in serum,n_1850,,,,,,,
effect/phenotype,Long-tract signs,n_1851,,,,,,,
effect/phenotype,Heterogeneous,n_1852,,,,,,,
effect/phenotype,Sleep-wake cycle disturbance,n_1853,,,,,,,
effect/phenotype,Middle age onset,n_1854,,,,,,,
effect/phenotype,Cognitive impairment,n_1855,,,,,,,
effect/phenotype,Parietal hypometabolism in FDG PET,n_1856,,,,,,,
effect/phenotype,Cerebral amyloid angiopathy,n_1857,,,,,,,
effect/phenotype,Senile plaques,n_1858,,,,,,,
effect/phenotype,Depressivity,n_1859,,,,,,,
effect/phenotype,Disinhibition,n_1860,,,,,,,
effect/phenotype,Hippocampal atrophy,n_1861,,,,,,,
effect/phenotype,Late onset,n_1862,,,,,,,
effect/phenotype,Neurological speech impairment,n_1863,,,,,,,
effect/phenotype,Cerebral cortex with spongiform changes,n_1865,,,,,,,
effect/phenotype,Behavioral abnormality,n_1869,,,,,,,
effect/phenotype,Emotional lability,n_1870,,,,,,,
effect/phenotype,Anxiety,n_1872,,,,,,,
effect/phenotype,Specific learning disability,n_1873,,,,,,,
effect/phenotype,Sleep disturbance,n_1874,,,,,,,
effect/phenotype,Deficit in phonologic short-term memory,n_1875,,,,,,,
effect/phenotype,Attention deficit hyperactivity disorder,n_1876,,,,,,,
effect/phenotype,Abdominal symptom,n_1877,,,,,,,
effect/phenotype,Perseveration,n_1878,,,,,,,
effect/phenotype,Jaw pain,n_1879,,,,,,,
effect/phenotype,Agitation,n_1881,,,,,,,
effect/phenotype,Hallucinations,n_1882,,,,,,,
effect/phenotype,Hypertonia,n_1883,,,,,,,
effect/phenotype,Confusion,n_1884,,,,,,,
effect/phenotype,Deposits immunoreactive to beta-amyloid protein,n_1885,,,,,,,
effect/phenotype,Abnormal social behavior,n_1886,,,,,,,
effect/phenotype,Neurodevelopmental abnormality,n_1887,,,,,,,
effect/phenotype,Abnormality of vision,n_1888,,,,,,,
effect/phenotype,Oculomotor apraxia,n_1889,,,,,,,
effect/phenotype,Intellectual disability,n_1890,,,,,,,
effect/phenotype,Ataxia,n_1891,,,,,,,
effect/phenotype,Aphasia,n_1892,,,,,,,
effect/phenotype,Abnormality of higher mental function,n_1893,,,,,,,
effect/phenotype,Semantic dementia,n_1894,,,,,,,
drug,Phenyltoloxamine,n_1900,,,,,,,
drug,Pheniramine,n_1901,,,,,,,
drug,Orphenadrine,n_1902,,,,,,,
drug,Pravastatin,n_1903,,,,,,,
drug,Carisoprodol,n_1904,,,,,,,
drug,Citric acid,n_1905,,,,,,,
drug,Butalbital,n_1906,,,,,,,
drug,Codeine,n_1907,,,,,,,
drug,Oxycodone,n_1908,,,,,,,
drug,Trolnitrate,n_1909,,,,,,,
drug,Salicylamide,n_1910,,,,,,,
drug,Phenacetin,n_1911,,,,,,,
drug,Phenylephrine,n_1912,,,,,,,
drug,Dipyridamole,n_1913,,,,,,,
drug,Caffeine,n_1914,,,,,,,
drug,Meprobamate,n_1915,,,,,,,
drug,Methocarbamol,n_1916,,,,,,,
drug,Phenobarbital,n_1917,,,,,,,
drug,Dextropropoxyphene,n_1918,,,,,,,
drug,Pentazocine,n_1919,,,,,,,
drug,Calcium gluconate,n_1920,,,,,,,
drug,Phenylpropanolamine,n_1921,,,,,,,
drug,Chlorpheniramine,n_1922,,,,,,,
drug,Hydrocodone,n_1923,,,,,,,
drug,Dihydrocodeine,n_1924,,,,,,,
drug,Epicriptine,n_1925,,,,,,,
drug,Perazine,n_1926,,,,,,,
drug,Alimemazine,n_1927,,,,,,,
drug,Isopropamide,n_1928,,,,,,,
drug,Molindone,n_1929,,,,,,,
drug,Fluphenazine,n_1930,,,,,,,
drug,Pramiracetam,n_1931,,,,,,,
drug,Methotrimeprazine,n_1932,,,,,,,
drug,Promazine,n_1933,,,,,,,
drug,Perphenazine,n_1934,,,,,,,
drug,Prochlorperazine,n_1935,,,,,,,
drug,Clozapine,n_1936,,,,,,,
drug,Fluoxetine,n_1937,,,,,,,
drug,Chlorpromazine,n_1939,,,,,,,
drug,Thioridazine,n_1940,,,,,,,
drug,Amitriptyline,n_1941,,,,,,,
drug,Propiomazine,n_1942,,,,,,,
drug,Thiothixene,n_1943,,,,,,,
drug,Acetylcarnitine,n_1944,,,,,,,
drug,Acetophenazine,n_1945,,,,,,,
drug,Pimozide,n_1946,,,,,,,
drug,Loxapine,n_1947,,,,,,,
drug,Ziprasidone,n_1948,,,,,,,
drug,Triflupromazine,n_1949,,,,,,,
drug,Paliperidone,n_1950,,,,,,,
drug,Iloperidone,n_1951,,,,,,,
drug,Olanzapine,n_1952,,,,,,,
drug,Aripiprazole,n_1953,,,,,,,
drug,Trifluoperazine,n_1954,,,,,,,
drug,Chlorprothixene,n_1955,,,,,,,
drug,Quetiapine,n_1956,,,,,,,
drug,Asenapine,n_1959,,,,,,,
drug,Ipidacrine,n_1961,,,,,,,
effect/phenotype,Morphological central nervous system abnormality,n_1973,,,,,,,
gene/protein,A2M,n_1974,,,,,,,
gene/protein,ACHE,n_1976,,,,,,,
gene/protein,ADAM10,n_1978,,,,,,,
gene/protein,AMFR,n_1980,,,,,,,
gene/protein,BIN1,n_1982,,,,,,,
gene/protein,APOC1,n_1984,,,,,,,
gene/protein,APOE,n_1986,,,,,,,
gene/protein,APP,n_1988,,,,,,,
gene/protein,ATP5F1A,n_1990,,,,,,,
gene/protein,BAX,n_1992,,,,,,,
gene/protein,BCHE,n_1994,,,,,,,
gene/protein,BCL2,n_1996,,,,,,,
gene/protein,BDNF,n_1998,,,,,,,
gene/protein,CALM1,n_2000,,,,,,,
gene/protein,CASP3,n_2002,,,,,,,
gene/protein,CD33,n_2004,,,,,,,
gene/protein,CHRNA7,n_2006,,,,,,,
gene/protein,CHRNB2,n_2008,,,,,,,
gene/protein,CLU,n_2010,,,,,,,
gene/protein,TPP1,n_2012,,,,,,,
gene/protein,CR1,n_2014,,,,,,,
gene/protein,CRH,n_2016,,,,,,,
gene/protein,CST3,n_2018,,,,,,,
gene/protein,CYP2D6,n_2020,,,,,,,
gene/protein,ACE,n_2022,,,,,,,
gene/protein,DHCR24,n_2024,,,,,,,
gene/protein,DPYSL2,n_2026,,,,,,,
gene/protein,EIF2S1,n_2028,,,,,,,
gene/protein,ENO1,n_2030,,,,,,,
gene/protein,EPHA1,n_2032,,,,,,,
gene/protein,ESR1,n_2034,,,,,,,
gene/protein,F2,n_2036,,,,,,,
gene/protein,GSK3B,n_2038,,,,,,,
gene/protein,HFE,n_2040,,,,,,,
gene/protein,HLA-DRB5,n_2042,,,,,,,
gene/protein,HMOX1,n_2044,,,,,,,
gene/protein,IDE,n_2046,,,,,,,
gene/protein,IGF1,n_2048,,,,,,,
gene/protein,IGF1R,n_2050,,,,,,,
gene/protein,IGF2,n_2052,,,,,,,
gene/protein,IGF2R,n_2054,,,,,,,
gene/protein,IL1B,n_2056,,,,,,,
gene/protein,INS,n_2058,,,,,,,
gene/protein,INPP5D,n_2060,,,,,,,
gene/protein,INSR,n_2062,,,,,,,
gene/protein,LEP,n_2064,,,,,,,
gene/protein,MAOB,n_2066,,,,,,,
gene/protein,MAPT,n_2068,,,,,,,
gene/protein,MPO,n_2070,,,,,,,
gene/protein,MTHFR,n_2072,,,,,,,
gene/protein,NOS3,n_2074,,,,,,,
gene/protein,NPY,n_2076,,,,,,,
gene/protein,PLAU,n_2078,,,,,,,
gene/protein,PLCG2,n_2080,,,,,,,
gene/protein,PPARG,n_2082,,,,,,,
gene/protein,PRNP,n_2084,,,,,,,
gene/protein,RELN,n_2086,,,,,,,
gene/protein,PSEN1,n_2088,,,,,,,
gene/protein,PSEN2,n_2090,,,,,,,
gene/protein,PYY,n_2092,,,,,,,
gene/protein,NECTIN2,n_2094,,,,,,,
gene/protein,SLC2A4,n_2096,,,,,,,
gene/protein,SOD2,n_2098,,,,,,,
gene/protein,SORL1,n_2100,,,,,,,
gene/protein,TF,n_2102,,,,,,,
gene/protein,TFAM,n_2104,,,,,,,
gene/protein,TNF,n_2106,,,,,,,
gene/protein,TPI1,n_2108,,,,,,,
gene/protein,VEGFA,n_2110,,,,,,,
gene/protein,VSNL1,n_2112,,,,,,,
gene/protein,SLC30A4,n_2114,,,,,,,
gene/protein,PICALM,n_2116,,,,,,,
gene/protein,UNC5C,n_2118,,,,,,,
gene/protein,ADAMTS1,n_2120,,,,,,,
gene/protein,ABCA7,n_2122,,,,,,,
gene/protein,TOMM40,n_2124,,,,,,,
gene/protein,PGRMC1,n_2126,,,,,,,
gene/protein,CYP46A1,n_2128,,,,,,,
gene/protein,ARC,n_2130,,,,,,,
gene/protein,NCSTN,n_2132,,,,,,,
gene/protein,CD2AP,n_2134,,,,,,,
gene/protein,BACE1,n_2136,,,,,,,
gene/protein,GAPDHS,n_2138,,,,,,,
gene/protein,PCDH11X,n_2140,,,,,,,
gene/protein,ABI3,n_2142,,,,,,,
gene/protein,MS4A4A,n_2144,,,,,,,
gene/protein,WWOX,n_2146,,,,,,,
gene/protein,TREM2,n_2148,,,,,,,
gene/protein,SLC30A6,n_2150,,,,,,,
gene/protein,CASS4,n_2152,,,,,,,
gene/protein,IQCK,n_2154,,,,,,,
gene/protein,MIR100,n_2156,,,,,,,
gene/protein,MIR146A,n_2158,,,,,,,
gene/protein,MIR296,n_2160,,,,,,,
gene/protein,MIR375,n_2162,,,,,,,
gene/protein,MIR505,n_2164,,,,,,,
gene/protein,MIR766,n_2166,,,,,,,
gene/protein,MIR708,n_2168,,,,,,,
gene/protein,SNAR-I,n_2170,,,,,,,
gene/protein,MIR3622B,n_2172,,,,,,,
gene/protein,MIR4467,n_2174,,,,,,,
gene/protein,ND1,n_2176,,,,,,,
gene/protein,ND2,n_2177,,,,,,,
disease,tauopathy,n_2179,,,,,,,
disease,dementia (disease),n_2180,,,,,,,
disease,Mendelian disease,n_2181,,,,,,,
disease,inherited disease susceptibility,n_2185,,,,,,,
disease,autosomal dominant disease,n_2186,,,,,,,
disease,inherited neurodegenerative disorder,n_2187,,,,,,,
disease,genetic dementia,n_2188,,,,,,,
disease,inherited prion disease,n_2189,,,,,,,
exposure,Aluminum,n_2190,,,,,,,
exposure,Cadmium,n_2191,,,,,,,
exposure,Metals,n_2192,,,,,,,
exposure,Nitrogen Oxides,n_2193,,,,,,,
exposure,Ozone,n_2194,,,,,,,
exposure,Particulate Matter,n_2195,,,,,,,
exposure,Pesticides,n_2196,,,,,,,
exposure,Silicon Dioxide,n_2197,,,,,,,
pathway,Neurodegenerative Diseases,n_2198,,,,,,,
gene/protein,BCL2L11,n_2199,,,,,,,
gene/protein,CDK5,n_2200,,,,,,,
gene/protein,FOXO3,n_2201,,,,,,,
gene/protein,GOLGA2,n_2202,,,,,,,
gene/protein,FASLG,n_2204,,,,,,,
gene/protein,JUN,n_2205,,,,,,,
gene/protein,LMNA,n_2206,,,,,,,
gene/protein,LMNB1,n_2207,,,,,,,
gene/protein,PRDX1,n_2208,,,,,,,
gene/protein,PRDX2,n_2210,,,,,,,
gene/protein,YWHAE,n_2211,,,,,,,
gene/protein,CAPN1,n_2212,,,,,,,
gene/protein,CAPN2,n_2213,,,,,,,
gene/protein,CAPNS1,n_2214,,,,,,,
gene/protein,CAST,n_2215,,,,,,,
gene/protein,CAPNS2,n_2216,,,,,,,
gene/protein,CDK5R1,n_2217,,,,,,,
gene/protein,CDC25A,n_2218,,,,,,,
gene/protein,CDC25B,n_2219,,,,,,,
gene/protein,CDC25C,n_2220,,,,,,,
Phenotypes,Memory loss for recent events,n_2224,,,,,,,
Phenotypes,Difficulty learning new information,n_2225,,,,,,,
Phenotypes,Subtle language problems,n_2226,,,,,,,
Phenotypes,Significant memory loss,n_2227,,,,,,,
Phenotypes,Confusion in daily activities,n_2228,,,,,,,
Phenotypes,Behavioral changes,n_2229,,,,,,,
Phenotypes,Severe memory loss,n_2230,,,,,,,
Phenotypes,Complete dependence on others,n_2231,,,,,,,
Phenotypes,Physical symptoms,n_2232,,,,,,,
Evidence,High quality (Level A),n_2242,,,,,,,
Evidence,Moderate quality (Level B),n_2243,,,,,,,
Duration,1 month,n_2257,,,,,,,
Population,increased if tolerated and necessary,n_2260,,,,,,,
Effectiveness,Significant improvement in cognitive scores and daily activities,n_2261,,,,,,,
Population,Mild to Severe Alzheimer's Disease (MMSE 0-26),n_2262,,,,,,,
Duration,4 week,n_2267,,,,,,,
Duration,least 4 week,n_2270,,,,,,,
Dosage,Galantamine 16-24mg/day,n_2272,,,,,,,
Population,Mild to moderate Alzheimer's Disease (MMSE 0-26),n_2273,,,,,,,
Duration,1 week,n_2277,,,,,,,
Population,moderate hepatic impairment,n_2281,,,,,,,
Dosage,Rivastigmine 1.5-6.0 twice daily,n_2284,,,,,,,
Duration,6 week,n_2292,,,,,,,
Dosage,Rivastigmine Patch 13.3mg/day,n_2294,,,,,,,
Dosage,Memantine 5-20 mg/day,n_2298,,,,,,,
Effectiveness,Significant improvement in cognitive decline and behavioral symptoms,n_2299,,,,,,,
Population,Moderate to severe Alzheimer's Disease (MMSE < 20),n_2300,,,,,,,
Dosage,Memantine 10-20 mg/day,n_2303,,,,,,,
Population,eGFR is 3049 mL/minute/1.73 m簡,n_2305,,,,,,,
Dosage,Memantine 10 mg/day,n_2308,,,,,,,
Population,eGFR is 5 - 29 mL/minute/1.73 m簡,n_2310,,,,,,,
Dosage,Haloperidol 0.5-5 mg/day,n_2313,,,,,,,
Duration,no more than 6 weeks,n_2314,,,,,,,
SideEffect,Nausea,n_2319,,,,,,,
SideEffect,Vomiting,n_2320,,,,,,,
SideEffect,Anorexia,n_2321,,,,,,,
SideEffect,Diarrhea,n_2322,,,,,,,
SideEffect,Muscle cramps,n_2323,,,,,,,
SideEffect,Syncope,n_2324,,,,,,,
SideEffect,Headache,n_2325,,,,,,,
SideEffect,Dizziness,n_2326,,,,,,,
SideEffect,Abnormal dreams,n_2327,,,,,,,
SideEffect,Hallucinations,n_2328,,,,,,,
SideEffect,Agitation,n_2329,,,,,,,
SideEffect,Aggression,n_2330,,,,,,,
SideEffect,Urinary incontinence,n_2331,,,,,,,
SideEffect,Rash,n_2332,,,,,,,
SideEffect,Pruritus,n_2333,,,,,,,
SideEffect,Extrapyramidal symptoms,n_2334,,,,,,,
SideEffect,Sinoatrial block,n_2335,,,,,,,
SideEffect,Atrioventricular (AV) block,n_2336,,,,,,,
SideEffect,Liver dysfunction (including hepatitis),n_2337,,,,,,,
SideEffect,Neuroleptic malignant syndrome (NMS),n_2338,,,,,,,
SideEffect,Fatigue,n_2339,,,,,,,
SideEffect,Insomnia,n_2340,,,,,,,
SideEffect,Abdominal pain,n_2343,,,,,,,
SideEffect,Diarrhoea,n_2344,,,,,,,
SideEffect,Dyspepsia,n_2345,,,,,,,
SideEffect,Decreased appetite,n_2346,,,,,,,
SideEffect,Weight loss ,n_2347,,,,,,,
SideEffect,Bradycardia,n_2348,,,,,,,
SideEffect,Hypertension,n_2349,,,,,,,
SideEffect,Depression,n_2352,,,,,,,
SideEffect,Tremor,n_2354,,,,,,,
SideEffect,Malaise,n_2357,,,,,,,
SideEffect,Muscle spasm,n_2358,,,,,,,
SideEffect,Retching,n_2359,,,,,,,
SideEffect,Dehydration,n_2360,,,,,,,
SideEffect,Hypotension,n_2361,,,,,,,
SideEffect,Flushing,n_2362,,,,,,,
SideEffect,Palpitation,n_2363,,,,,,,
SideEffect,Arrhythmias,n_2364,,,,,,,
SideEffect,First-degree AV block,n_2365,,,,,,,
SideEffect,Taste disturbance,n_2366,,,,,,,
SideEffect,Paraesthesia,n_2367,,,,,,,
SideEffect,Seizures,n_2368,,,,,,,
SideEffect,Hypersomnia,n_2369,,,,,,,
SideEffect,Muscular weakness,n_2370,,,,,,,
SideEffect,Blurred vision,n_2371,,,,,,,
SideEffect,Tinnitus,n_2372,,,,,,,
SideEffect,Sweating,n_2373,,,,,,,
SideEffect,Exacerbation of Parkinson's disease,n_2374,,,,,,,
SideEffect,Hepatitis,n_2375,,,,,,,
SideEffect,Serious skin reactions,n_2376,,,,,,,
SideEffect,Weight loss,n_2382,,,,,,,
SideEffect,Drowsiness,n_2387,,,,,,,
SideEffect,Gait abnormalities,n_2388,,,,,,,
SideEffect,Fall,n_2389,,,,,,,
SideEffect,Anxiety,n_2392,,,,,,,
SideEffect,Confusion,n_2394,,,,,,,
SideEffect,Parkinsonism,n_2396,,,,,,,
SideEffect,Skin reactions,n_2398,,,,,,,
SideEffect,Urinary tract infection,n_2399,,,,,,,
SideEffect,Atrial fibrillation,n_2402,,,,,,,
SideEffect,AV block,n_2403,,,,,,,
SideEffect,Gastric and duodenal ulceration,n_2407,,,,,,,
SideEffect,Pancreatitis,n_2408,,,,,,,
SideEffect,Angina,n_2409,,,,,,,
SideEffect,Restlessness,n_2414,,,,,,,
SideEffect,Sick sinus syndrome,n_2415,,,,,,,
SideEffect,Tachycardia,n_2416,,,,,,,
SideEffect,Constipation,n_2418,,,,,,,
SideEffect,Dyspnoea,n_2420,,,,,,,
SideEffect,Impaired balance,n_2423,,,,,,,
SideEffect,Thrombosis,n_2426,,,,,,,
SideEffect,Heart failure,n_2427,,,,,,,
SideEffect,Abnormal gait,n_2431,,,,,,,
SideEffect,Psychosis,n_2434,,,,,,,
SideEffect,Suicidal ideation,n_2436,,,,,,,
SideEffect,Weight gain,n_2438,,,,,,,
SideEffect,Dyslipidaemia,n_2439,,,,,,,
SideEffect,Hyperprolactinaemia,n_2440,,,,,,,
SideEffect,Sedation,n_2441,,,,,,,
SideEffect,Sleep apnoea syndrome,n_2442,,,,,,,
SideEffect,Anticholinergic effects,n_2443,,,,,,,
SideEffect,Postural hypotension,n_2444,,,,,,,
SideEffect,Reduced seizure threshold,n_2446,,,,,,,
SideEffect,Impaired glucose tolerance,n_2447,,,,,,,
SideEffect,"Cardiomyopathy, myocarditis, and cutaneous vasculitis",n_2448,,,,,,,
SideEffect,QT interval prolongation,n_2449,,,,,,,
SideEffect,Stroke risk,n_2450,,,,,,,
SideEffect,Venous thromboembolism (VTE),n_2451,,,,,,,
SideEffect,Pneumonia,n_2453,,,,,,,
SideEffect,Neutropenia,n_2454,,,,,,,
SideEffect,Abnormal liver function tests (LFTs),n_2455,,,,,,,
SideEffect,Photosensitivity,n_2456,,,,,,,
SideEffect,Skin and subcutaneous tissue disorders,n_2457,,,,,,,
SideEffect,Diplopia,n_2458,,,,,,,
SideEffect,Misuse and abuse,n_2459,,,,,,,
SideEffect,Restless legs syndrome,n_2460,,,,,,,
Effectiveness,Improves memory attention and social interaction,n_2493,,,,,,,
Effectiveness,Helps maintain long-term memory improves mood,n_2494,,,,,,,
Effectiveness,Reduces anxiety and agitation improves daily functioning,n_2495,,,,,,,
Effectiveness,Improves mood reduces agitation provides positive emotions,n_2496,,,,,,,
Phenotypes,Severe cardiac arrhythmia,n_2497,,,,,,,
Phenotypes,Pregnancy and breastfeeding.,n_2498,,,,,,,
Phenotypes,"Known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipients used in the formulation",n_2499,,,,,,,
Phenotypes,"History of bradycardia, heart block, recurrent unexplained syncope.",n_2500,,,,,,,
Phenotypes,Concurrent treatment with drugs that reduce heart rate.,n_2501,,,,,,,
Phenotypes,Sick sinus syndrome or other supraventricular conduction abnormalities.,n_2502,,,,,,,
Phenotypes,Susceptibility to peptic ulcers including concurrent nonsteroidalanti inflammatory(NSAID) use.,n_2503,,,,,,,
Phenotypes,Asthma and chronic obstructive pulmonary disease (COPD).,n_2504,,,,,,,
Phenotypes,Hepatic impairment.,n_2505,,,,,,,
Phenotypes,Concomitant antipsychotic treatment  increased risk of neuroleptic malignant syndrome (NMS).,n_2506,,,,,,,
Phenotypes,Hypersensitivity to galantamine or to any of the excipients.,n_2508,,,,,,,
Phenotypes,Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 9 mL/minute/1.73 m簡).,n_2509,,,,,,,
Phenotypes,Severe hepatic impairment (Child-Pugh score greater than 9).,n_2510,,,,,,,
Phenotypes,People who have both significant renal and hepatic dysfunction.,n_2511,,,,,,,
Phenotypes,Urinary outflow obstruction.,n_2512,,,,,,,
Phenotypes,Gastrointestinal obstruction.,n_2513,,,,,,,
Phenotypes,During recovery from bladder or gastrointestinal surgery.,n_2514,,,,,,,
Phenotypes,Renal and hepatic impairment.,n_2516,,,,,,,
Phenotypes,"Cardiac disease or in those who use medicinal products that significantly reduce heart rate concomitantly, such as digoxin and beta blockers.",n_2517,,,,,,,
Phenotypes,QTc interval prolongation or taking drugs that prolong the QTc interval.,n_2518,,,,,,,
Phenotypes,Electrolyte disturbances (such as hyperkalaemia or hypokalaemia).,n_2519,,,,,,,
Phenotypes,"Susceptibility to peptic ulcers, including concomitant use of NSAIDs.",n_2520,,,,,,,
Phenotypes,"History of severe asthma, COPD, or pulmonary infection.",n_2521,,,,,,,
Phenotypes,History of seizures.,n_2522,,,,,,,
Phenotypes,"Known hypersensitivity to rivastigmine, other carbamate derivatives, or to any of the excipients used in the formulation.",n_2523,,,,,,,
Phenotypes,Previous history of application site reactions suggestive of allergic contact dermatitis with the rivastigmine patch.,n_2524,,,,,,,
Phenotypes,Renal impairment.,n_2527,,,,,,,
Phenotypes,Gastric or duodenal ulcers (or susceptibility to ulcers).,n_2528,,,,,,,
Phenotypes,Sick sinus syndrome or conduction abnormalities.,n_2529,,,,,,,
Phenotypes,History of asthma or COPD.,n_2530,,,,,,,
Phenotypes,Bladder outflow obstruction.,n_2532,,,,,,,
Phenotypes,"Pre-existing, or a family history of, QT interval prolongation.",n_2533,,,,,,,
Phenotypes,Higher risk of developing torsade de pointes,n_2534,,,,,,,
Phenotypes,"Hypersensitivity to the active substance or to any of the excipients, including people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.",n_2535,,,,,,,
Phenotypes,Severe hepatic impairment.,n_2536,,,,,,,
Phenotypes,Severe renal impairment  memantine hydrochloride should be avoided if the estimated glomerular filtration rate (eGFR) is less than 5 mL/minute/1.73 m簡.,n_2537,,,,,,,
Phenotypes,History of convulsions or predisposing factors for epilepsy.,n_2538,,,,,,,
Phenotypes,Severe renal impairment,n_2539,,,,,,,
Phenotypes,"Central nervous system depression, comatose states.",n_2540,,,,,,,
Phenotypes,"Congenital long QT syndrome, history of Torsade de Pointes, QTc interval",n_2541,,,,,,,
Phenotypes,"prolongation, concurrent use with drugs that prolong the QT interval, history of",n_2542,,,,,,,
Phenotypes,"ventricular arrhythmias, recent myocardial infarction, uncompensated heart failure.",n_2543,,,,,,,
Phenotypes,Uncorrected hypokalaemia.,n_2544,,,,,,,
Phenotypes,Progressive supranuclear palsy.,n_2545,,,,,,,
Phenotypes,Dementia with Lewy bodies.,n_2546,,,,,,,
Phenotypes,Parkinson's disease.,n_2547,,,,,,,
Phenotypes,Blood dyscrasias.,n_2548,,,,,,,
Phenotypes,"Cardiovascular disease  an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, personal history of cardiovascular disease.",n_2549,,,,,,,
Phenotypes,Conditions predisposing to seizures.,n_2550,,,,,,,
Phenotypes,Depression.,n_2551,,,,,,,
Phenotypes,Diabetes (may raise blood glucose).,n_2552,,,,,,,
Phenotypes,Epilepsy.,n_2553,,,,,,,
Phenotypes,History of jaundice.,n_2554,,,,,,,
Phenotypes,Myasthenia gravis.,n_2555,,,,,,,
Phenotypes,Parkinson宎s disease (may be exacerbated).,n_2556,,,,,,,
Phenotypes,Photosensitization (may occur with higher dosages).,n_2557,,,,,,,
Phenotypes,Prostatic hypertrophy.,n_2558,,,,,,,
Phenotypes,Severe respiratory disease.,n_2559,,,,,,,
Phenotypes,Susceptibility to angle-closure glaucoma,n_2560,,,,,,,
Phenotypes,Bradycardia.,n_2561,,,,,,,
Phenotypes,Uncorrected electrolyte disturbances.,n_2562,,,,,,,
Phenotypes,Family history of QTc-interval prolongation.,n_2563,,,,,,,
Phenotypes,History of heavy alcohol exposure.,n_2564,,,,,,,
Phenotypes,Hyperthyroidism.,n_2565,,,,,,,
Phenotypes,Hypotension (including orthostatic hypotension).,n_2566,,,,,,,
Phenotypes,Prolactin-dependent tumours.,n_2567,,,,,,,
Phenotypes,Prolactinaemia.,n_2568,,,,,,,
Phenotypes,Risk factors for stroke.,n_2569,,,,,,,
Phenotypes,Hypersensitivity to risperidone or to any of the excipients.,n_2570,,,,,,,
Phenotypes,Acute porphyrias.,n_2571,,,,,,,
Phenotypes,Cataract surgery (risk of intra-operative floppy iris syndrome).,n_2572,,,,,,,
Phenotypes,Dehydration.,n_2573,,,,,,,
Monitoring,Weight monthly,n_2589,,,,,,,
Duration,4-6 week,n_2597,,,,,,,
Dosage,Donepezil 5-10 mg/day,n_2599,,,,,,,
Dosage,Rivastigmine 1.5-6mg/day*2,n_2602,,,,,,,
Treatment,Galantamine  Treatment (NICE),n_2603,,,,,,,
Dosage,Galantamine 4mg/day*2,n_2606,,,,,,,
Dosage,Memantine 5-20mg/day,n_2611,,,,,,,
SideEffect,decreased appetite,n_2618,,,,,,,
SideEffect,Depressed,n_2626,,,,,,,
SideEffect,Weight lose,n_2641,,,,,,,
SideEffect,Hallucination,n_2646,,,,,,,
SideEffect,Myalgia,n_2647,,,,,,,
Phenotypes,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",n_2654,,,,,,,
Phenotypes,"Difficulties with basic activities of daily living (e.g. feeding,dressing).",n_2656,,,,,,,
Phenotypes,Fully dependent,n_2658,,,,,,,
Evidence,Moderate to Low quality,n_2684,,,,,,,
Duration,12-24 week,n_2688,,,,,,,
Population,Mild to Severe Alzheimer's Disease (MMSE 0-26) (ADAS-Cog),n_2689,,,,,,,
Duration,26 week,n_2693,,,,,,,
Dosage,Rivastigmine,n_2697,,,,,,,
Duration,Rivastigmine,n_2698,,,,,,,
Population,Rivastigmine,n_2699,,,,,,,
Treatment,Rivastigmine,n_2700,,,,,,,
SideEffect,Rivastigmine,n_2708,,,,,,,
Therapy,Rivastigmine,n_2721,,,,,,,
Effectiveness,Rivastigmine,n_2725,,,,,,,
Evidence,Rivastigmine,n_2743,,,,,,,
Step,Rivastigmine,n_2753,,,,,,,
Phenotypes,Rivastigmine,n_2957,,,,,,,
THERAPY_EFFECTIVENESS,Rivastigmine,n_3080,,,,,,,
Population,Mild to moderate Alzheimer's Disease (MMSE 10-26),n_3192,,,,,,,
Dosage,Memantine 20 mg/day,n_3195,,,,,,,
Dosage,Memantine 28 mg/day,n_3199,,,,,,,
Evidence,Low quality (Level C),n_3204,,,,,,,
Effectiveness,attenuates worsening of physical function and activities of daily living,n_3206,,,,,,,
Effectiveness,"improving BPSD, including anxiety",n_3207,,,,,,,
Treatment,Suvorexant,n_3210,,,,,,,
Treatment,Donepezil Treatment (Alzheimer Society of B.C.),n_3222,,,,,,,
Treatment,Memantine Treatment (Alzheimer Society of B.C.),n_3223,,,,,,,
Phenotypes,memory loss,n_3225,,,,,,,
Phenotypes,cognitive ability loss,n_3226,,,,,,,
Phenotypes,Difficultly coming up with the right word or name.,n_3227,,,,,,,
Phenotypes,Difficultly remembering names when introduced to new people.,n_3228,,,,,,,
Phenotypes,Having difficulty performing tasks in social or work settings.,n_3229,,,,,,,
Phenotypes,Forgetting material that was just read.,n_3230,,,,,,,
Phenotypes,Losing or misplacing a valuable object.,n_3231,,,,,,,
Phenotypes,Experiencing increased trouble with planning or organizing.,n_3232,,,,,,,
Phenotypes,Being forgetful of events or personal history.,n_3233,,,,,,,
Phenotypes,"Feeling moody or withdrawn, especially in socially or mentally challenging situations.",n_3234,,,,,,,
Phenotypes,"Being unable to recall information about themselves like their address or telephone number, and the high school or college they attended.",n_3235,,,,,,,
Phenotypes,Experiencing confusion about where they are or what day it is.,n_3236,,,,,,,
Phenotypes,Requiring help choosing proper clothing for the season or the occasion.,n_3237,,,,,,,
Phenotypes,Having trouble controlling their bladder and bowels.,n_3238,,,,,,,
Phenotypes,"Experiencing changes in sleep patterns, such as sleeping during the day and becoming restless at night.",n_3239,,,,,,,
Phenotypes,Showing an increased tendency to wander and become lost.,n_3240,,,,,,,
Phenotypes,"Demonstrating personality and behavioral changes, including suspiciousness and delusions or compulsive, repetitive behavior like hand-wringing or tissue shredding.",n_3241,,,,,,,
Phenotypes,Require around-the-clock assistance with daily personal care.,n_3242,,,,,,,
Phenotypes,Lose awareness of recent experiences as well as of their surroundings.,n_3243,,,,,,,
Phenotypes,"Experience changes in physical abilities, including walking, sitting and, eventually, swallowing",n_3244,,,,,,,
Phenotypes,Have difficulty communicating.,n_3245,,,,,,,
Phenotypes,"Become vulnerable to infections, especially pneumonia.",n_3246,,,,,,,
Population,MCI to Mild Alzheimer's Disease,n_3249,,,,,,,
Population,Mild to severe Alzheimer's Disease,n_3255,,,,,,,
Population,Mild to moderate Alzheimer's Disease,n_3258,,,,,,,
Population,Moderate to severe Alzheimer's Disease,n_3264,,,,,,,
Population,Agitation associated with dementia due to Alzheimer's disease,n_3271,,,,,,,
Population,Insomnia,n_3274,,,,,,,
SideEffect,ARIA,n_3276,,,,,,,
SideEffect,headache,n_3277,,,,,,,
SideEffect,Infusion-related reactions,n_3278,,,,,,,
SideEffect,Loss of appetite,n_3283,,,,,,,
SideEffect,Increased frequency of bowel movements,n_3285,,,,,,,
SideEffect,Sleepiness,n_3299,,,,,,,
SideEffect,Common cold symptoms,n_3301,,,,,,,
SideEffect,Restlessness or feeling like  need to move,n_3302,,,,,,,
SideEffect,Impaired alertness and motor coordination,n_3303,,,,,,,
SideEffect,Worsening of depression or suicidal thinking,n_3304,,,,,,,
SideEffect,Complex sleep behaviors,n_3305,,,,,,,
SideEffect,Sleep paralysis,n_3306,,,,,,,
SideEffect,Compromised respiratory function,n_3307,,,,,,,
Therapy,Maintain regular times for meals and for going to bed and getting up,n_3308,,,,,,,
Therapy,Seek morning sunlight exposure,n_3309,,,,,,,
Therapy,"Encourage regular daily exercise, but no later than four hours before bedtime",n_3310,,,,,,,
Therapy,"Avoid alcohol, caffeine and nicotine",n_3311,,,,,,,
Therapy,Treat any pain,n_3312,,,,,,,
Therapy,"If the person is taking a cholinesterase inhibitor (tacrine, donepezil, rivastigmine or galantamine), avoid giving the medicine before bed",n_3313,,,,,,,
Therapy,Make sure the bedroom temperature is comfortable,n_3314,,,,,,,
Therapy,Provide nightlights and security objects,n_3315,,,,,,,
Therapy,"If the person awakens, discourage staying in bed while awake; use the bed only for sleep",n_3316,,,,,,,
Therapy,Discourage watching television during periods of wakefulness,n_3317,,,,,,,
Symptom,Memory loss for recent events,n_3321,,,,,,,
Symptom,Difficulty learning new information,n_3322,,,,,,,
Symptom,Subtle language problems,n_3323,,,,,,,
Symptom,Significant memory loss,n_3324,,,,,,,
Symptom,Confusion in daily activities,n_3325,,,,,,,
Symptom,Behavioral changes,n_3326,,,,,,,
Symptom,Severe memory loss,n_3327,,,,,,,
Symptom,Complete dependence on others,n_3328,,,,,,,
Symptom,Physical symptoms,n_3329,,,,,,,
Effectiveness,small significant benefit on cognitive function and ADL,n_3346,,,,,,,
Duration,Review every 6 months,n_3357,,,,,,,
Effectiveness,significant effect on ADL function at 24 weeks,n_3358,,,,,,,
Duration,2 weeks,n_3363,,,,,,,
SideEffect,Gastrointestinal,n_3372,,,,,,,
SideEffect,Falls,n_3375,,,,,,,
Condition,Severe renal impairment,n_3381,,,,,,,
Monitoring,Cognitive function (MMSE) every 6 months,n_3382,,,,,,,
disease,dementia,n_3454,,,,,,,
disease,cognitive impairment,n_3455,,,,,,,
disease,Alzheimer's disease,n_3456,,,,,,,
disease,MCI,n_3457,,,,,,,
disease,Dementia,n_3458,,,,,,,
disease,Alzheimer's Disease,n_3469,,,,,,,
disease,cognitive Impairment,n_3554,,,,,,,
disease,Cognitive impairment,n_3571,,,,,,,
source,American Academy of Family Physicians,es_1,Guideline,American Academy of Family Physicians,Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1,,USA
source,Alzheimer Society,es_2,Guideline,Alzheimer Society,Dementia treatment options and developments,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1,,Canada
source,Alzheimer's Association,es_3,Guideline,Alzheimer's Association,"Medications for Memory, Cognition and Dementia-Related Behaviors",https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1,,USA
source,The Association of Scientific Medical Societies in Germany,es_4,Guideline,The Association of Scientific Medical Societies in Germany,S3-Leitlinie Demenzen Langfassung,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1,,Germany
source,Cognitive Decline Partnership Centre,es_5,Guideline,Cognitive Decline Partnership Centre,Clinical Practice Guidelines and Principles of Care for People with Dementia,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1,,Australia
source,Cochrane Library,es_6,Systematic Review,Cochrane Library,Cholinesterase inhibitors for Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005593/abstract,2006/1/25,,
source,Cochrane Library,es_7,Systematic Review,Cochrane Library,Memantine for dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub5/full,2006/4/19,,
source,Cochrane Library,es_8,Systematic Review,Cochrane Library,Exercise programs for people with dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006489.pub4/full,2015/4/15,,
source,Cochrane Library,es_9,Systematic Review,Cochrane Library,Music therapy for people with dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003477.pub2/full,2003/10/20,,
source,Cochrane Library,es_10,Systematic Review,Cochrane Library,Donepezil for dementia due to Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021/1/1,,
source,Cochrane Library,es_11,Systematic Review,Cochrane Library,Galantamine for Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full,2015/1/1,,
source,Cochrane Library,es_12,Systematic Review,Cochrane Library,Rivastigmine for Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub2/full,2004/1/1,,
source,Cochrane Library,es_13,Systematic Review,Cochrane Library,Memantine for dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub5/full,2019/3/20,30891742.0,
source,Electronic Medicines Compendium,es_14,Database,Electronic Medicines Compendium,Risperidone 1 mg Orodispersible Tablets,https://www.medicines.org.uk/emc/product/4353/smpc,2023/1/15,,
source,International Journal of Neuropsychopharmacology,es_15,Journal Article,International Journal of Neuropsychopharmacology,Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimers Disease: A Systematic Review and Meta-Analysis ,https://academic.oup.com/ijnp/article/18/5/pyu115/786398?login=false,2017/7/1,,
source,Journal of the American Medical Association,es_16,Journal Article,Journal of the American Medical Association,Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease,https://jamanetwork.com/journals/jama/fullarticle/1810379#google_vignette,2014/1/1,,
source,Japanese Society of Neurology,es_17,Guideline,Japanese Society of Neurology,Clinical Practice Guideline for Dementia 2017,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1,,Japan
source,Ministry of Health Malaysia,es_18,Guideline,Ministry of Health Malaysia,MANAGEMENT OF DEMENTIA (THIRD EDITION),https://www.moh.gov.my/moh/resources/Main%20Banner/2021/Jun/Draft_CPG_Management_of_Dementia_(Third_Edition).pdf,2021/1/31,,Malaysia
source,成功大學,es_19,Guideline,成功大學,失智症用藥安全指導,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1,,Taiwan
source,National Institute for Health and Care Excellence,es_20,Guideline,National Institute for Health and Care Excellence,The NICE Clinical Knowledge Summaries,https://cks.nice.org.uk/topics/dementia/,2024/4/1,,UK
source,Health Technol Assess,es_21,Journal Article,Health Technol Assess,"The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model",https://pubmed.ncbi.nlm.nih.gov/22541366/,2012/1/1,22541366.0,
source,臺中榮總,es_22,Guideline,臺中榮總,失智症疾病照護團隊臨床照護計畫診療指引,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21,,Taiwan
source,Cochrane Database of Systematic Reviews,Burckhardt20,Cochrane Library,Cochrane Database of Systematic Reviews,Souvenaid for Alzheimer's disease,,2020/1/1,,
source,Cochrane Database of Systematic Reviews,Ruthirakuhan18,Cochrane Library,Cochrane Database of Systematic Reviews,Pharmacological interventions for apathy in Alzheimer's disease,,2018/1/1,,
source,Cochrane Database of Systematic Reviews,Birks03,Cochrane Library,Cochrane Database of Systematic Reviews,Donepezil for dementia due to Alzheimer's disease,,2018/1/1,,
source,Cochrane Database of Systematic Reviews,Liu16,Cochrane Library,Cochrane Database of Systematic Reviews,Treatment of epilepsy for people with Alzheimer's disease,,2021/1/1,,
source,Cochrane Database of Systematic Reviews,Farina00,Cochrane Library,Cochrane Database of Systematic Reviews,Vitamin E for Alzheimer's dementia and mild cognitive impairment,,2017/1/1,,
source,Cochrane Database of Systematic Reviews,Mühlbauer21,Cochrane Library,Cochrane Database of Systematic Reviews,Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia,,2021/1/1,,
source,Cochrane Database of Systematic Reviews,Lombardi20,Cochrane Library,Cochrane Database of Systematic Reviews,Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment,,2020/1/1,,
source,Cochrane Database of Systematic Reviews,Chau15,Cochrane Library,Cochrane Database of Systematic Reviews,Latrepirdine for Alzheimer's disease,,2015/1/1,,
source,Cochrane Database of Systematic Reviews,Birks00,Cochrane Library,Cochrane Database of Systematic Reviews,Rivastigmine for Alzheimer's disease,,2015/1/1,,
source,Cochrane Database of Systematic Reviews,Martínez17,Cochrane Library,Cochrane Database of Systematic Reviews,18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI),,2017/1/1,,
source,Cochrane Database of Systematic Reviews,Kokkinou21,Cochrane Library,Cochrane Database of Systematic Reviews,Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting,,2021/1/1,,
source,Cochrane Database of Systematic Reviews,Kudlicka23,Cochrane Library,Cochrane Database of Systematic Reviews,Cognitive rehabilitation for people with mild to moderate dementia,,2023/1/1,,
source,Cochrane Database of Systematic Reviews,Taylor-Rowan23,Cochrane Library,Cochrane Database of Systematic Reviews,Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment,,2023/1/1,,
source,Cochrane Database of Systematic Reviews,Karkou17,Cochrane Library,Cochrane Database of Systematic Reviews,Dance movement therapy for dementia,,2023/1/1,,
source,Cochrane Database of Systematic Reviews,Lim02,Cochrane Library,Cochrane Database of Systematic Reviews,Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment,,2024/1/1,,
source,Cochrane Database of Systematic Reviews,Burckhardt16,Cochrane Library,Cochrane Database of Systematic Reviews,Omega‐3 fatty acids for the treatment of dementia,,2016/1/1,,
source,Cochrane Database of Systematic Reviews,Seitz18,Cochrane Library,Cochrane Database of Systematic Reviews,Mini‐Cog for the detection of dementia within a primary care setting,,2021/1/1,,
source,Cochrane Database of Systematic Reviews,McGuinness01,Cochrane Library,Cochrane Database of Systematic Reviews,Statins for the prevention of dementia,,2016/1/1,,
source,Cochrane Database of Systematic Reviews,Cunningham09,Cochrane Library,Cochrane Database of Systematic Reviews,Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia,,2021/1/1,,
source,Cochrane Database of Systematic Reviews,Smailagic15,Cochrane Library,Cochrane Database of Systematic Reviews,18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI),,2015/1/1,,
source,Cochrane Database of Systematic Reviews,Parsons21,Cochrane Library,Cochrane Database of Systematic Reviews,"Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia",,2021/1/1,,
source,Cochrane Database of Systematic Reviews,Ritchie17,Cochrane Library,Cochrane Database of Systematic Reviews,CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI),,2017/1/1,,
source,Cochrane Database of Systematic Reviews,Arevalo-Rodriguez15,Cochrane Library,Cochrane Database of Systematic Reviews,Mini‐Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI),,2021/1/1,,
source,Cochrane Database of Systematic Reviews,Creavin22,Cochrane Library,Cochrane Database of Systematic Reviews,Clinical judgement by primary care physicians for the diagnosis of all‐cause dementia or cognitive impairment in symptomatic people,,2022/1/1,,
source,Cochrane Database of Systematic Reviews,Fage15,Cochrane Library,Cochrane Database of Systematic Reviews,Mini‐Cog for the detection of dementia within a community setting,,2021/1/1,,
source,Cochrane Database of Systematic Reviews,Chan19,Cochrane Library,Cochrane Database of Systematic Reviews,Mini‐Cog for the detection of dementia within a secondary care setting,,2021/1/1,,
source,Cochrane Database of Systematic Reviews,Creavin16,Cochrane Library,Cochrane Database of Systematic Reviews,Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations,,2016/1/1,,
source,Cochrane Database of Systematic Reviews,McCleery15,Cochrane Library,Cochrane Database of Systematic Reviews,Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies,,2015/1/1,,
source,Cochrane Database of Systematic Reviews,Kwan22,Cochrane Library,Cochrane Database of Systematic Reviews,Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia,,2022/1/1,,
source,Cochrane Database of Systematic Reviews,Reilly15,Cochrane Library,Cochrane Database of Systematic Reviews,Case management approaches to home support for people with dementia,,2015/1/1,,
source,Cochrane Database of Systematic Reviews,Davis15,Cochrane Library,Cochrane Database of Systematic Reviews,Montreal Cognitive Assessment for the detection of dementia,,2021/1/1,,
source,Cochrane Database of Systematic Reviews,Herke18,Cochrane Library,Cochrane Database of Systematic Reviews,Environmental and behavioural modifications for improving food and fluid intake in people with dementia,,2018/1/1,,
source,Cochrane Database of Systematic Reviews,McCleery14,Cochrane Library,Cochrane Database of Systematic Reviews,Pharmacotherapies for sleep disturbances in dementia,,2020/1/1,,
source,Cochrane Database of Systematic Reviews,Li15,Cochrane Library,Cochrane Database of Systematic Reviews,Cholinesterase inhibitors for rarer dementias associated with neurological conditions,,2015/1/1,,
source,Cochrane Database of Systematic Reviews,Visser18,Cochrane Library,Cochrane Database of Systematic Reviews,"Community‐based supplementary feeding for food insecure, vulnerable and malnourished populations – an overview of systematic reviews",,2018/1/1,,
source,Cochrane Database of Systematic Reviews,McShane03,Cochrane Library,Cochrane Database of Systematic Reviews,Memantine for dementia,,2019/1/1,,
source,Cochrane Database of Systematic Reviews,Tammenmaa‐Aho02,Cochrane Library,Cochrane Database of Systematic Reviews,Cholinergic medication for antipsychotic‐induced tardive dyskinesia,,2018/1/1,,
source,Cochrane Database of Systematic Reviews,McGuinness16,Cochrane Library,Cochrane Database of Systematic Reviews,Statin withdrawal in people with dementia,,2016/1/1,,
source,Cochrane Database of Systematic Reviews,Jordan20,Cochrane Library,Cochrane Database of Systematic Reviews,Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia,,2020/1/1,,
source,Cochrane Database of Systematic Reviews,Bahar‐Fuchs19,Cochrane Library,Cochrane Database of Systematic Reviews,Cognitive training for people with mild to moderate dementia,,2019/1/1,,
source,Cochrane Database of Systematic Reviews,Cui13,Cochrane Library,Cochrane Database of Systematic Reviews,Cerebrolysin for vascular dementia,,2019/1/1,,
source,Cochrane Database of Systematic Reviews,Todd06,Cochrane Library,Cochrane Database of Systematic Reviews,"Conservative, physical and surgical interventions for managing faecal incontinence and constipation in adults with central neurological diseases",,2024/1/1,,
source,Cochrane Database of Systematic Reviews,Battle21,Cochrane Library,Cochrane Database of Systematic Reviews,Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis,,2021/1/1,,
source,Cochrane Database of Systematic Reviews,Ure23,Cochrane Library,Cochrane Database of Systematic Reviews,Acetylcholinesterase inhibitors for autistic spectrum disorders,,2023/1/1,,
source,Cochrane Database of Systematic Reviews,McCleery18,Cochrane Library,Cochrane Database of Systematic Reviews,Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment,,2018/1/1,,
source,Cochrane Database of Systematic Reviews,Burry19,Cochrane Library,Cochrane Database of Systematic Reviews,Pharmacological interventions for the treatment of delirium in critically ill adults,,2019/1/1,,
source,Cochrane Database of Systematic Reviews,Punjasawadwong18,Cochrane Library,Cochrane Database of Systematic Reviews,Processed electroencephalogram and evoked potential techniques for amelioration of postoperative delirium and cognitive dysfunction following non‐cardiac and non‐neurosurgical procedures in adults,,2018/1/1,,
source,Cochrane Database of Systematic Reviews,Woods12,Cochrane Library,Cochrane Database of Systematic Reviews,Cognitive stimulation to improve cognitive functioning in people with dementia,,2023/1/1,,
source,Cochrane Database of Systematic Reviews,Livingstone15,Cochrane Library,Cochrane Database of Systematic Reviews,Pharmacological interventions for cognitive decline in people with Down syndrome,,2015/1/1,,
source,Cochrane Database of Systematic Reviews,Archer15,Cochrane Library,Cochrane Database of Systematic Reviews,Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementia,,2015/1/1,,
source,MONDO,s_0,PrimeKG,MONDO,,,,,
source,MONDO_grouped,s_1,PrimeKG,MONDO_grouped,,,,,
source,REACTOME,s_2,PrimeKG,REACTOME,,,,,
source,HPO,s_3,PrimeKG,HPO,,,,,
source,DrugBank,s_4,PrimeKG,DrugBank,,,,,
source,NCBI,s_5,PrimeKG,NCBI,,,,,
source,CTD,s_6,PrimeKG,CTD,,,,,
source,EMC,s_7,PrimeKG,EMC,,,,,
source,JAMA,s_8,PrimeKG,JAMA,,,,,
source,IJN,s_9,PrimeKG,IJN,,,,,
source,pubmed,s_10,PrimeKG,pubmed,,,,,
